A little less than a year after launching Rhopressa (netarsudil), its first drug for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals Inc. has won FDA approval for Rocklatan, a once-daily eye drop that adds the widely prescribed prostaglandin analogue (PGA) latanoprost to the mix.